Day One Bio Day One Bio

OJEMDATM (tovorafenib) has been approved in the United States by the Food and Drug Administration for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

OJEMDA is no longer available for expanded access or compassionate use in the United States.

OJEMDA may be available to patients outside of the United States contingent upon meeting eligibility criteria and subject, in certain circumstances, to receiving local regulatory approval. To receive more information about access to tovorafenib outside the United States please contact [email protected]

You are now leaving the Day One Biopharmaceuticals Corporate Website

You will now be redirected to the requested website. Please confirm that you want to proceed.